BioSpace News Archive

Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application.

Anelto, a leader in Remote Patient Monitoring (RPM) solutions, today announced it has entered into a channel partnership with BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, to integrate BioIntelliSense’s FDA-cleared BioSticker™ and BioButton® wearable medical devices and data services with Anelto’s RemoteCareLive! RPM platform.

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today its abstracts were accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, in Chicago.

Onera Health, a leader in transforming sleep medicine and remote monitoring, announced today that its wholly-owned subsidiary in the Netherlands, Onera B.V., has received 510(k) market clearance from the U.S. Food & Drug Administration (FDA) for its ground-breaking system for Polysomnography (PSG) studies, Onera STS, paving the way for widespread deployment of the patch-based technology across healthcare systems in the U.S.

Co-Diagnostics, Inc. announced today it will release its first quarter 2022 results on Thursday, May 12, 2022 , after the market close.

ReviR Therapeutics announced today the appointment of Dr. David Dornan as an independent director.

Providing excellent care inside and outside of the traditional hospital is the new normal for patients, clinicians, and payers seeking more choices without compromising excellent outcomes.

HighTide Therapeutics, Inc. announced that the first patient was dosed in a phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM) in China.

Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the details of its oral abstract presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

According to Vision Research Reports, the global generic drugs market was estimated at USD 414.56 billion in 2021 and it is expected to reach USD 574.63 billion by 2027, expanding growth at a CAGR of 5.59% from 2021 to 2027.